J Kurebayashi
Overview
Explore the profile of J Kurebayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pushkarev V, Starenki D, Saenko V, Namba H, Kurebayashi J, Tronko M, et al.
Endocrinology
. 2004 Mar;
145(7):3143-52.
PMID: 15044368
Understanding the detailed mechanisms of a chemotherapeutic agent action on cancer cells is essential for planning the clinical applications because drug effects are often tissue and cell type specific. This...
2.
Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H
Br J Cancer
. 2004 Jan;
90(1):236-44.
PMID: 14710235
A high expression level of epidermal growth factor receptor (EGFR)/HER1 has been suggested to lead to a shorter survival time and resistance to endocrine therapy in patients with breast cancer....
3.
Soga S, Sharma S, Shiotsu Y, Shimizu M, Tahara H, Yamaguchi K, et al.
Cancer Chemother Pharmacol
. 2002 Jan;
48(6):435-45.
PMID: 11800023
Purpose: Radicicol is a novel hsp90 antagonist, distinct from the chemically unrelated benzoquinone ansamycin compounds, geldanamycin and herbimycin. Both geldanamycin and radicicol bind in the aminoterminal nucleotide-binding pocket of hsp90,...
4.
Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo H
Jpn J Cancer Res
. 2001 Dec;
92(12):1342-51.
PMID: 11749701
A novel oxime derivative of radicicol, KF58333, binds to the heat shock protein 90 (Hsp90) and destabilizes its associated signaling molecules. These effects play a critical role in the growth...
5.
Uno M, Otsuki T, Kurebayashi J, Sakaguchi H, Isozaki Y, Ueki A, et al.
Int J Cancer
. 2001 Dec;
94(4):474-9.
PMID: 11745431
To explore the antiproliferative effects of rhumAbHER2 on head and neck squamous carcinoma cell (HNSCC) lines and breast cancer cell lines (BCCLs) and to evaluate the combined effects with irradiation,...
6.
Yamamoto S, Kurebayashi J, Kurosumi M, Kunisue H, Otsuki T, Tanaka K, et al.
Cancer Chemother Pharmacol
. 2001 Nov;
48(4):283-8.
PMID: 11710628
Purpose: Although several combination treatments with docetaxel and other antitumor agents have been tested in experimental and clinical studies, their synergistic effects are still ill-defined. The degree of synergism between...
7.
Kurebayashi J, Otsuki T, Moriya T, Sonoo H
Jpn J Cancer Res
. 2001 Oct;
92(10):1093-101.
PMID: 11676860
Resistance to hormonal therapy frequently occurs following successful treatment in breast cancer. The mechanism responsible for this acquired resistance is still unknown. It has been suggested that a hypoxic tumor...
8.
Yata K, Sadahira Y, Otsuki T, Sakaguchi H, Isozaki Y, Uno M, et al.
Br J Haematol
. 2001 Sep;
114(3):591-9.
PMID: 11552984
Among the recently discovered myeloma-specific gene alterations associated with chromosomal translocations, cyclin D1/PRAD1/Bcl-1 overexpression caused by t(11;14)(q13;q32) is considered to be the most frequent in myeloma patients and cell lines,...
9.
Sonoo H, Kurebayashi J
Gan To Kagaku Ryoho
. 2001 Aug;
28(7):909-16.
PMID: 11478139
Endocrine therapy of advanced or recurrent breast cancer was described. The presence of ER or PgR in primary breast tumors is the best-established marker for response to endocrine therapy. However,...
10.
Otsuki T, Yamada O, Kurebayashi J, Sakaguchi H, Yata K, Uno M, et al.
Leuk Lymphoma
. 2001 May;
41(3-4):397-409.
PMID: 11378553
To elucidate the role of PTHrP in myeloma, we examined the expression levels of PTHrP and its receptor in human myeloma cell lines and clinical specimens from 13 myeloma cases....